Cadi-05

N/A

Report date: 2026/04/16 20:00:17

Base Information

Drug NameCadi-05

Drug Alias NameMIP-vaccine-CadilaLeprosy vaccinePoly-toll-like receptor agonist polyantigenic vaccineCadi-MwPoly-TLR agonist polyantigenic vaccine +[9]

ClassificationVaccines > Application > Therapeutic vaccine

Mechanisms of ActionInterferon gamma stimulantsToll-like receptor agonists

TargetsInterferon gammaToll-like receptor

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and NeckLeprosy

Global Approved IndicationsCarcinoma, Non-Small-Cell LungLeprosy

Approved Indications in ChinaN/A

Original Approved Country/TerritoryIndia

Original Approved Date1998/01/01

Country/TerritoryUnited StatesIndia

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)

China Registration ClassN/A

Develop Information

Active CompaniesCadila Pharnmaceuticals

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and NeckLeprosy

Inactive IndicationsN/A

Other Information

ATC CodeJ07AX